BCM
BMY.RT

Bluefin Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bluefin Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-605,574
Closed -$418K – 1082
2020
Q4 		$418K Buy
+605,574
New +$1.29M 0.02% 317
2020
Q3 		– Sell
-1,860,353
Closed -$5.31M – 46
2020
Q2 		$6.66M Buy
1,860,353
+349,523
+23% +$1.26M 0.56% 26
2020
Q1 		$5.74M Sell
1,510,830
-600,568
-28% -$1.98M 0.74% 31
2019
Q4 		$6.36M Buy
+2,111,398
New +$5.49M 0.42% 67

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Bluefin Capital Management's BMY.RT Position: Q1 2021 in Review

Bluefin Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 605,574 shares — an estimated $418K sold.

Bluefin Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $6.66M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Bluefin Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Bluefin Capital Management sold 605,574 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $418K.
  • Bluefin Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Bluefin Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $6.66M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bluefin Capital Management's 13F filing for Q1 2021, filed 17 May 2021.